CancerAppy
Novel cancer therapeutic drugs
At CancerAppy, we specialize in cancer research, dedicated to discovering and developing new therapeutic targets. Our proprietary artificial intelligence methodology allows us to accelerate advancements in more effective cancer treatments
Driving innovation in breakthrough oncology treatments.
With our deep expertise in oncology and AI, we analyze vast amounts of multimodal data using advanced AI algorithms. This allows us to identify new therapeutic targets, discover lead compounds, understand their mechanisms of action, and explore potential drug combinations. Our technology also enables the development of next-generation antibody-drug conjugates (ADCs), driving more precise and effective cancer treatments.

We work in the early stage of the Drug Discovery Value Chain.

Our R&D Pipeline
At CancerAppy, we use AI-driven drug discovery to develop new cancer therapies, including novel ADCs (antibody-drug conjugates). Our pipeline moves from target discovery to preclinical development, bringing innovative treatments closer to patients.
News
Latest news about CancerAppy…
BIO Spain
We're excited to be part of BioSpain 2023, and despite our packed schedule, we welcome you to connect with us at the BasqueHealthCluster booth....
ATG symbio Spain
Cancerappy participated in the II international congress organized by ATG Symbio Spain that was held inBarcelona at the Biomedical Research Park...
Bio International Convention – Boston 23
Our CEO will be attending the BIO International in Boston from June 5th to 8th. Cancerappy is dedicated to the discovery and development of new...
Grant CPP2021-008597 funded by:

Grant TQ2020-011486 funded by:


Subvencionado por el CDTI

Somos cliente Enisa

